-
Uncategorized2 months ago
Odyssey Therapeutics will try again to IPO, this time in a warmer market
A year after pulling its first try at an IPO, Odyssey Therapeutics is giving it another go. On Friday night, the Boston-based biotech submitted its second...
-
Uncategorized2 months ago
Comprehensive profiling of clinically approved kinase inhibitors reveals mutation-specific inhibitors and opportunities for drug repurposing
Nature Biotechnology, Published online: 20 April 2026; doi:10.1038/s41587-026-03090-8 A large screen of approved kinase inhibitors expands the druggable kinome.
-
Uncategorized2 months agoSTAT+: AACR 2026: More strong data for Revolution Medicines’ KRAS drug
You’re reading the web version of STAT’s popup newsletter, AACR in 30 seconds, your guide to what’s happening at the American Association of Cancer Researchers’ annual...
-
Uncategorized2 months ago
StockWatch: Revolution’s Phase III Pancreatic Cancer Data Dazzles Investors, Analysts
Pancreatic cancer is one of the most difficult cancers to treat, with an overall five-year survival rate of 13%, according to the American Cancer Society, stretching...
-
Uncategorized2 months agoSTAT+: The race to catch KRAS, pancreatic cancer’s ‘greasy ball,’ and create the most promising drug in decades
Leanna Stokes had gotten into the habit of asking her oncologist what might be next for her treatment, and for good reason. Stokes, a 36-year-old gymnastics...
-
Uncategorized2 months ago10x Genomics Unveils Atera Spatial Platform at AACR Meeting
The genomics community’s long wait for 10x Genomics’ highly anticipated news is finally over. On Saturday night, at the Hard Rock Café Hotel in San Diego—across...
-
Uncategorized2 months ago
Three gene therapy pioneers just won the Breakthrough Prize. This is their story
A trio of scientists behind the first gene therapy approved in the United States have been awarded a Breakthrough Prize in Life Sciences. It’s arguably one...
-
Uncategorized2 months agoHow Trump is pushing psychedelics reform through the health agencies
WASHINGTON — President Trump moved on Saturday to “reverse the crisis of serious mental illness in America” by boosting access to psychedelic drugs in clinical settings....
-
Uncategorized2 months agoOptimism for Trump’s CDC pick is tempered by questions about RFK Jr.’s role
The nomination of a new leader for the Centers for Disease Control and Prevention — one who has scientific credentials and no public ties to the...
-
Uncategorized2 months ago
RevMed’s stunning success; FDA to reclassify peptides; and more
RevMed’s stunning success; FDA to reclassify peptides; and more
STAT+: Up and down the ladder: The latest comings and goings
FDA imposes import alert on Indian plant after inspectors flag GMP failings
